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ABSTRACT
Two chalcone derivatives i.e.  (E)-1-(4-aminophenyl)-3-(2,3dimethoxyphenyl)-prop-2-en-1-
one (Compound-1), and (E)-1-(4-aminophenyl)-3-phenylprop-2-en-1-one) (Compound-2), 
has been proven to have potential cytotoxic activity. The aim of this study was to 
evaluate the effect of these compounds on PI3K/Akt signalling pathway in K562 cell 
lines. After incubation with the tested compounds, AKT, caspase-3, STAT3 and cyclin 
D1 concentrations were measured using ELISA. Furthermore, cell cycle was analysed 
using flowcytometry. Imatinib and isotretinoin were used as positive control, whereas 
cell culture without treatment was used as negative control. The AKT concentration after 
treatment with Compound-1 and -2 was significantly lower than that control, imatinib 
and isotretinoin (p<0.05). The apoptotic indices after treatment with Compound-1 and 
-2 were significantly higher than control, however they were lower than imatinib and 
isotretinoin (p<0.05). The caspase-3 concentration after treatment with Compound-1 at 
5 and 10 µg/mL and Compound-2 at 10 µg/mL was significantly higher than that control 
and imatinib, however it was lower than isotretinoin (p<0.05). The STAT3 concentration 
after treatment with Compound-1 and -2 was significantly lower than that control and 
isotretinoin at 50 µg/mL (p<0.05) and similar with imatinib (p>0.05). The cyclin D1 
concentration after treatment with Compound-1 and -2 was significantly lower than that 
control, imatinib and isotretinoin (p<0.05). In addition, Compound-1 and -2 arrested G0/
G1 and G2/M phase in K562 cell lines, with comparable results to imatinib and isotretinoin. 
In conclusion, the mechanism of cytotoxic activity of Compound-1 and -2  are through the 
PI3K/Akt signalling pathway inhibition, apoptosis induction by upregulation of apoptotic 
markers, and inhibition of cell cycle progression by regulating cell cycle-related factors.
ABSTRAK
Dua turunan kalcon yaitu (E)-1-(4-aminofenil)-3-(2,3dimetoksifenil)-prop-2-en-1-one 
(Senyawa-1), and (E)-1-(4-aminofenil)-3-fenilprop-2-en-1-one) (Senyawa-2), terbukti 
mempunyai aktivitas sitotoksik yang potensial. Tujuan penelitian ini adalah untuk 
mengkaji efek kedua senyawa tersebut pada jalur sinyal PI3K/Akt pada sel K562. Setelah 
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diinkubasikan dengan senyawa uji, kadar AKT, caspase-3, STAT3 dan siklin D1 diukur 
dengan ELISA. Selanjutnya siklus sel dianalisis dengan flowcyometry. Imatinib dan 
isotretinoin digunakan sebagai kontrol positif dan kultur sel tanpa perlakuan sebagai kontrol 
negatif. Kadar AKT setelah perlakuan dengn Senyawa-1 dan -2 lebah rendah secara nyata 
dibaningkan dengan kontrol, imatiib dan isotretinoin (p<0.05).  Indeks apoptosis setelah 
perlakuan dengan Senyawa-1 dan -2 lebih tinggi secara nyata dibandingkan kontrol, tetapi 
lebih rendah dibandingkan imatinib dan isotretinoin (p<0.05). Kadar caspase-3 setelah 
perlakuan Senyawa-1 dengan kadar 5 dan 10 µg/mL dan Senyawa-2 dengan kadar 10 
µg/mL lebih tinggi secara nyata dibandingkan kontrol dan imatinib, tetapi lebih rendah 
dibandingkan dengan isotretinoin (p<0.05). Kadar STAT3 setelah perlakuan dengan 
Senyawa-1 dan -2 lebih rendah secara nyata dibandingkan control dan isotretinoin kadar 50 
µg/mL (p<0.05) dan setara dengan imatinib (p>0.05). Kadar siklin D1 setelah perlakuan 
dengan Senyawa-1 dan -2 lebih rendah secara nyata dibandingkan dengan kontrol, imatinib 
dan isotretinoin (p<0.05). Senyawa-1 dan -2 terbukti menghambat siklus sel K562 pada 
fase G0/G1 dan G2/M yang sebanding dengan imatinib dan isotretinoin. Dapat disimpulkan, 
mekannisne aktivitas sitotoksik senyawa-1 dan -2 melalui penghambatan jalur sinyal PI3K/
Akt, induksi apoptosis melalui upregulasi penanda apoptosis dan penghambatan siklus sel 
melalui pengaruhnya terhadap factor-faktor yang berhubungan dengan pengaturan siklus 
sel.       
Keywords : anticancer - chalcone derivatives – leukemia – K562 cell line - PI3K/Akt 
signaling
INTRODUCTION
Leukemia is a cancer of the white blood 
cells characterized by the widespread, rapid, 
and disorderly proliferation of leukocytes.1,2 
Leukemia is a rare disease; however, it 
exceeds the number of deaths caused by 
acute communicable diseases due to its fatal 
character.2 In 2012, leukemia was suffered 
by approximately 352,000 people around 
the world and caused 265,000 deaths.3 
The PI3K/Akt signaling pathway plays an 
important role in both normal and malignant 
hematopoiesis.4,5 The activity of AKT is 
regulated by P13K, which brings AKT into 
the cell membrane upon PIP3 binding, which 
is activated by PDK1.6 Activated AKT is 
an essential survival factor which inhibits 
apoptosis through phosphorylation of several 
targets, including Bad, FoxO transcription 
factors, Raf-1 and caspase-9.7 AKT also 
activates the transcription activator (STAT3), 
which is critical for leukemia cell survival 
and proliferation.8 Activation of STAT3 leads 
to tumor-promoting gene products, including 
cleavage caspase-3, cleavage poly ADP-ribose 
polymerase (PARP), cyclin D1, and survivin. 
Thus, these pathways are commonly targeted 
in cancer treatments.
Until now, chemotherapy is still one 
of the effective strategies for the treatment 
of cancer.9 However, the use of anticancer 
treatments as chemotherapy is limited. All 
of the current anticancer drugs have severe 
side effects in normal cells due to their non-
specificity. In addition, the resistance of cancer 
cells to anticancer drugs remains a significant 
challenge to successful chemotherapy.10 
Therefore, the discovery and development of 
new anticancer treatments with specific targets 
and novel mechanisms are urgently needed.
Chalcones are precursors of flavonoids, 
which are abundantly found in plants, and are 
reported to possess anticancer activity. Several 
chalcones have been isolated or synthesized, 
and their cytotoxicity on cancer cell lines 
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and their anticancer activity in cancer animal 
models have been reported.11,12 Furthermore, 
the molecular mechanisms of the anticancer 
action of chalcones have also been investigated. 
The chalcones exhibited anticancer activity 
through multiple mechanisms including cell 
cycle disruption, angiogenesis inhibition, 
tubulin polymerization inhibition, apoptosis 
induction and blockade of the nuclear factor-
kappa B (NF-κB) signaling pathway.12,13
We previously evaluated the cytotoxic 
activity of several chalcone derivatives on 
the K562 leukemia cell line, resulting in two 
chalcones showing the highest activity  i.e. (E)-
1-(4-aminophenyl)-3-(2,3 dimethoxyphenyl)-
prop-2-en-1-one (Compound-1), and (E)-1-
(4-aminophenyl)-3-phenylprop-2-en-1-one) 
(Compound-2). In this study we reported 
the mechanism of cytotoxic activity of these 
compounds through their effect on the level 
of AKT, caspase-3, STAT3, cyclin D1, and 
cell cycle on K562 leukemia cell lines. 
Furthermore, imatinib and isotretinoin were 
used as positive control in this study. 
MATERIALS AND METHODS 
Tested compounds
The methoxy amino chalcone derivatives 
were synthesized by Suwito et al.14 The 
structure of these compounds is presented in 
FIGURE 1. 
FIGURE 1. Chemical structure chalcone derivatives
Cell culture
The K562 cell lines were obtained from 
Stem Cells and Cancer Institute (SCI) Jakarta, 
Indonesia. The cell lines were maintained in 
iscove’s modified dulbeco’s medium (Biowest 
L0190-500) supplemented by 10% fetal 
bovine serum (FBS) (Biowest S181H2), and 
2% penicilin-streptomycin (Biowest L0022-
100) and incubated at 37oC in a 5% CO2 
atmosphere with 95% humidity. After 24 hours 
of incubation, the number of viable cells was counted 
using a haemocytometer with tryphan blue staining.
Measurement of AKT, caspase-3, STAT3 
and cyclin D1 concentrations in K562 cell 
lines culture
The concentration of AKT was determined 
using an ELISA kit (ab176657). After pre-
incubation of K562 cell lines treated with 
imatinib (10 and 50 µg/mL), isotretinoin (25 
and 50 µg/mL), Compound-1 and -2 (5 and 
10 µg/mL), 50 μL of sample was added to 
wells, and then 50 μL of the antibody was 
added into each well, and incubated for 1 hour 
at room temperature. Each well was washed 
with 350 μL of wash buffer. One hundred μL 
of TMB substrate was added into each well, 
and incubated for 15 minutes in the dark. The 
reaction was stopped by adding 100 μL of 
stop solution to each well. Absorbance was 
measured  using Multiskan GO Microplate 
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Spectrophotometer at 450 nm. Untreated 
K562 cell lines served as control. 
The similar methods were applied 
to determine the caspase-3 and STAT3 
concentrations using different antibody i.e. 
ELISA kit ab181418 for caspase-3, ELISA 
kit ab176666 for STAT3 and biotinylated 
detection antibody for cyclin D1.   
Cell cycle analysis
Cells (2 × 106 cells/well) were cultured 
in 24-well plates, and then treated with 0.1% 
DMSO, and 100 µL tested compounds at an 
appropriate final concentration (10 and 20 
µg/mL for imatinib;  25 and 50 µg/mL for 
isotretinoin; 5 and 10 µg/mL for Compound-1 
and -2, before being incubated for 24 hr. Cells 
were harvested, washed using PBS, fixed in 
70% ethanol overnight and stained with 50 μg/
mL PI and 20 µg/mL RNAse. Data acquisition 
and analysis were performed on a MACSQuant 
Analyzer 10 flowcytometer (Miltenyil Biotec), 
and data from 500,000 cells were collected 
for each data file. Cell cycle analysis was 
performed with MACSQuantify™ Software 
(Miltenyil Biotec).
Statistical analysis
Data were presented as means ± standard 
deviation (SD). SPSS (Version 16, SPSS Inc., 
Chicago, IL, USA) was used to perform one-
way analysis of variance (ANOVA) to analysis 
the different among group means. Duncan’s 
multiple range test  was used to validate 
significant differences for all treatments. A 
p value <0.05 was considered significantly 
different.
RESULTS
AKT concentration in K562 cell lines
AKT concentration on K562 cell lines 
of all treatments is presented in FIGURE 2. 
The AKT concentration of all treatments was 
significantly lower than control (p<0.05) 
except on isotretinoin treatment at 50 µg/mL 
which it was significantly higher (p<0.05). 
The AKT concentration after treatment 
with Compound-1 at 5 µg/mL (2.45 ng/
mL) and Compound-2 at 10 µg/mL (2.42 
ng/mL) were lower than control (12.74 ng/
mL).  The similar results were observed after 
treatment with Compound-2 at 5 and 10 µg/
mL in which the AKT concentrations were 
2.42 and 2.97 ng/mL, respectively. The lower 
AKT concentrations were also observed 
after imatinib treatment at 10 and 20 µg/mL 
in which the AKT concentrations were 4.30 
and 3.91 ng/mL, respectively. In contrast, the 
AKT concentration was higher (16.56 ng/mL) 
after treatment with isotretinoin at 50 µg/mL. 
However, it was also higher (7.15 ng/mL) 
after treatment with isotretinoin at 25 µg/mL. 
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FIGURE 2.  AKT total concentration on K562 cell lines after treatment 
with imatinib, isotretinoin, Compound-1 and -2. (*) indicates a 
significant difference between treatments compared to control 
(p<0.05). 
Apoptotic index and caspase-3 in K562 cell 
lines
Effects of chalcone derivatives on 
apoptosis in K562 cell lines as indicated in the 
caspase-3 concentration and apoptotic index 
are shown in FIGURE 3 and 4. The apoptotic 
indices in K562 cell lines of all treatments 
were significantly higher than control 
(p<0.05). The highest apoptotic indices were 
observed after treatment with imatinib 20 
µg/mL (6.89%) and isotretinoin 50 µg/mL 
(6.84%). The apoptotic indices after treatment 
with Compound-1 at 10 µg/mL, Compound-2 
at 10 µg/mL and control were 3.89, 4.03 and 
2.33%, respectively.  
FIGURE 3.  Apoptotic index on K562 cell lines after treatment with imatinib, isotretinoin, 
Compound-1 and -2. (*) indicates a significant difference between treatments 
compared to control (p<0.05).
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The caspase-3 concentrations on K562 
cell lines after treatment with Compound-1 
at 5 µg/mL (1.19 ng/mL), Compound-1 at 10 
µg/mL (1.37 ng/mL) and Compound-2 at 10 
µg/mL (0.66 ng/mL) were significantly higher 
than control (0.26 ng/mL) (p<0.05). The 
similar results were observed after treatment 
with imatinib at 10 and 20 µg/mL in which the 
caspase-3 concentrations were 2.97 and 2.83 
ng/mL, respectively (p<0.05). No significantly 
different in caspase-3 concentrations compare 
to control were observed treatment with 
isotretinoin at 25 µg/mL (0.24 ng/mL) and at 
50 µg/mL (0.22 ng/mL) (p>0.05). 
FIGURE 4.  Caspase-3 concentration on K562 cell lines after treatment with imatinib, 
isotretinoin, Compound-1 and -2. (*) indicates a significant difference 
between treatments compared to control (p<0.05).
STAT3 concentration in K562 cell lines
STAT3 concentration on K562 cell lines 
of all treatments is presented in FIGURE 5. 
The STAT3 concentration of all treatments 
was significantly lower than control (p<0.05) 
except on isotretinoin treatment at 25 µg/
mL which it was not significantly different 
(p>0.05). The STAT3 concentrations after 
treatment with Compound-1 at 5 µg/mL (9.00 
ng/mL), Compound-1 at 10 µg/mL (5.48 ng/
mL), Compound-2 at 5 µg/mL (8.62 ng/mL) 
and Compound-2 at 10 µg/mL (14.77 ng/
mL) were significantly lower than control 
(37.56 ng/mL) (p<0.05). The similar results 
were observed after treatment with imatinib at 
10 and 20 µg/mL and isotretinoin at 50 µg/
mL in which the STAT3 concentrations were 
10.11,  7.83 and 21.51 ng/mL, respectively 
(p<0.05). No significantly different in STAT3 
concentrations compare to control was 
observed treatment with isotretinoin at 25 µg/
mL (38.68 ng/mL) (p>0.05).  
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FIGURE 5. STAT3 concentration on K562 cell lines after treatment with imatinib, 
isotretinoin, Compound-1 and -2. (*) indicates a significant difference 
between treatments compared to control (p<0.05).
Cyclin D1 concentration in K562 cell lines 
and cell cycle
Cyclin D1 concentration on K562 cell 
lines and its cell cycle of all treatments are 
presented in FIGURE 6 and 7. The cyclin 
D1 concentration of all treatments was 
significantly lower than control (p<0.05). 
The cyclin D1 concentrations after treatment 
with Compound-1 at 5 µg/mL (1.41 ng/mL), 
Compound-1 at 10 µg/mL (1.51 ng/mL), 
Compound-2 at 5 µg/mL (1.45 ng/mL) and 
Compound-2 at 10 µg/mL (1.47 ng/mL) were 
also significantly lower than imatinib 10 µg/
mL (4.53 ng/mL), imatinib 20 µg/mL (3.43 ng/
mL), isotretinoin 25 µg/mL (5.85 ng/mL) and 
isotretinoin 50 µg/mL (4.62 ng/mL) (p<0.05). 
FIGURE 6. Cyclin D1 concentration on K562 cell lines after treatment with imatinib, 
isotretinoin, Compound-1 and -2. (*) indicates a significant difference between 
treatments compared to control (p<0.05).
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As shown in FIGURE 7, Compound-2 
at 5 µg/mL was the only compound that 
significantly arrested G0/G1 phase (32.42%), 
and it was comparable to imatinib of 20 µg/
mL (35.99%) and isotretinoin of 25 and 50 
µg/mL (32.15 and 33.87%, respectively). 
Both Compound-1 at 5 and 10 µg/mL  (21.73 
and 22.01%, respectively) and Compound-2 
at 5 and 10 µg/mL (18.50 and 21.94%, 
respectively) significantly decreased S phase 
compared to control (32.52%). Compound-1 
and -2 at 10 µg/mL arrested G2/M phase 
(37.21 and 41.07%, respectively), which were 
comparable to imatinib at 10 µg/mL (38.45%).
FIGURE 7.  K562 cell cycle after treatment with imatinib, isotretinoin, Compound-1 and -2. (*) 
indicates a significant difference between treatments compared to control (p<0.05).
DISCUSSION
Chemotherapy is one of the most potent 
and effective strategies to treat cancer.9 
However, all of the anticancer therapies 
that are currently available have severe side 
effects on normal cells due to their non-
specificity, leading to the development of 
new anticancer therapies with specific targets. 
Molecular mechanisms of cancer have been 
studied in drug discovery. The PI3K/Akt 
signaling pathway plays an important role in 
both normal and malignant hematopoiesis.4,5 
Activated AKT is critical for leukemia cell 
survival and proliferation,8 and is known to 
function as an essential survival factor by 
inhibiting apoptosis.7 These pathways are 
commonly targeted in cancer treatments.
Almost all treatments in the present study 
significantly decreased AKT levels on K562 
cells, except isotretinoin at 25 µg/mL, which 
increased the AKT level. Both Compound-1 
and -2 showed the most significant decrease 
among treatments. These findings are in 
accordance with previous studies that reported 
on chalcone derivatives as anticancer agents. 
Xu et al.,15 showed chalcone derivative, 
L2H17, inactivated NF-κB and AKT signaling 
pathways in colon cancer. The role of AKT 
in cancer involves the following: survival of 
cells by blocking the function of proapoptotic 
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proteins and processes; phosphorylation 
of Bad,16,17 that promotes release of Bad 
from heterodimeric of Bcl-2 and Bcl-XL; 
phosphorylation of MDM218,19 stabilizing 
it and promoting its translocation to the 
nucleus, where it triggers p53 degradation; 
and phosphorylation of XIAP, an inhibitor 
of caspase cascade, and thus inhibiting its 
degradation.20
In this study, Compound-1 and -2 also 
significantly increased caspase-3 on K562, 
as confirmed by the higher apoptotic index 
compared to the control. Chalcones have 
also been reported to induce apoptosis in 
cancer cells. Referring to a previous study, 
chalcones (1.3-diphenyl-2-propenone) in 
a human diet rich in fruits and vegetables 
inhibit the proliferation of T24 and HT-
1376 cells by inducing apoptosis. Chalcone 
increased the expression of Bax and Bak, but 
decreased the levels of Bcl-2 and Bcl-X(L) 
and subsequently triggered the mitochondrial 
apoptotic pathway (release of cytochrome c 
and activation of caspase-9 and caspase-3).21 
Apoptosis is by far the best-characterized type 
of cell death and is defined by morphologic 
modifications (chromatin condensation, 
loss of mitochondrial membrane potential, 
plasma membrane asymmetry, overall cell 
shrinkage, blebbing of the plasma membrane, 
and detachment from the cellular matrix), all 
occurring before the loss of plasma membrane 
integrity. Those modifications occur due to 
executioner caspase activation.22 
The results of the present study showed 
that all treatments decreased STAT3 on 
K562. These findings are validated by a 
previous study which showed that a chalcone 
derivative, 4,3′,4′,5′-tetramethoxychalcone, 
inhibits the phosphorylation of STAT3 and 
its upstream protein tyrosine kinase c-Src.23 
STAT3, an oncogenic transcription factor, is 
often constitutively active in human cancer 
cells.24 Activated STAT3 may up-regulate 
the expression of genes such as apoptosis 
inhibitors (Bcl-xl, Bcl-2), cell cycle regulators 
(cyclin D1) and oncogenic transcription 
factors (c-myc) in tumorigenesis.25,26
In this study, all treatments significantly 
decreased cyclin D1 levels on K562 cells. 
Compound-1 and -2 showed the highest 
decrease among treatments. The cyclin 
D1/CDK4 complex is responsible for cell 
cycle progression in early G1 phase, and is 
frequently overexpressed in various human 
carcinomas.27-29 Compound-1 and -2 also 
arrested G0/G1 and G2/M phase in K562 cells, 
with the results being comparable to imatinib 
and accutane. These findings are in agreement 
with a previous study that shows chalcone 
inhibits the proliferation of T24 and HT-1376 
cells by blocking cell cycle progression in 
the G2/M phase.
21 Another study investigated 
the effect of a synthetic chalcone derivative, 
4,3′,4′,5′- tetramethoxychalcone, that resulted 
in G0/G1 cell cycle arrest through the down-
regulation of cyclin D1 and CDK4, and the 
up-regulation of p16, p21 and p27 proteins 
in A2780 cells.23 The p16 protein is a 
specific inhibitor of CDK-cyclin D complex, 
preventing the phosphorylation of Rb and 
cell cycle reentry at G0/G1 phase.
27 Eukaryotic 
cell cycle progression involves sequential 
activation of cyclin-dependent kinases 
(CDK), whose activation is dependent on 
their association with cyclins.30 A complex 
formed by the association of Cdc2 (also 
known as Cdk1 or p34Cdc2) and cyclin D1 
plays a major role at entry into mitosis.30 The 
phosphorylation of Tyr15 of Cdc2 suppresses 
the activity of Cdk1/cyclin B1 kinase complex. 
Dephosphorylation of Tyr15 of Cdc2 is 
catalysed by Cdc25 phosphatases, and this 
reaction is believed to be the ratelimiting step 
for entry into mitosis.31 Cell cycle progression 
is also regulated by the relative balance 
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between the cellular concentration of CDK 
inhibitors, such as members of the CDK-
interacting protein/CDK-inhibitory protein 
(CIP/KIP) and inhibitor of CDK families, 
and that of cyclin-CDK complexes. The CIP/
KIP family, including CIP/p21, and KIP/p27, 
bind to cyclin-CDK complexes and prevent 
kinase activation and subsequently blocking 
the progression of the  cell cycle at the G0/G1 
or G2/M phases.
30,32
CONCLUSION
It can be concluded that (E)-1-(4-
aminophenyl)-3-(2,3 dimethoxyphenyl)-
prop-2-en-1-one (Compound-1), and (E)-1-
(4-aminophenyl)-3-phenylprop-2-en-1-one) 
(Compound-2) may be potential compounds 
to be developed as anticancer against 
leukemia. The molecular mechanisms of 
cytotoxic activity of these compounds in the 
K562 cell lines involved i) inhibition of the 
PI3K/Akt signaling pathway; ii) induction 
of apoptosis through the up-regulation of 
apoptotic markers; and iii) inhibition of cell 
cycle progression by regulating cell cycle-
related factors.
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